Radiopharmaceuticals EU-IN Horizon Scanning Report
Submitted by Anonymous (not verified) on 15 April 2026 - 13:52
Radiopharmaceuticals EU-IN Horizon Scanning Report
PSUSA/00000073/202507
Submitted by Anonymous (not verified) on 15 April 2026 - 11:35
PSUSA/00000073/202507
Human medicines European public assessment report (EPAR): Jorveza, budesonide, Date of authorisation: 08/01/2018, Revision: 7, Status: Authorised
Submitted by Anonymous (not verified) on 15 April 2026 - 11:12
Human medicines European public assessment report (EPAR): Jorveza, budesonide, Date of authorisation: 08/01/2018, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Bortezomib Hospira, bortezomib, Date of authorisation: 22/07/2016, Revision: 14, Status: Withdrawn
Submitted by Anonymous (not verified) on 15 April 2026 - 10:48
Human medicines European public assessment report (EPAR): Bortezomib Hospira, bortezomib, Date of authorisation: 22/07/2016, Revision: 14, Status: Withdrawn
Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 15 April 2026, 09:30 (CEST) to 15 April 2026, 13:00 (CEST)
Submitted by Anonymous (not verified) on 15 April 2026 - 9:00
Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 15 April 2026, 09:30 (CEST) to 15 April 2026, 13:00 (CEST)
Orphan designation: risvutatug rezetecan Treatment of pulmonary neuroendocrine carcinoma, 20/10/2025 Positive
Submitted by Anonymous (not verified) on 14 April 2026 - 16:00
Orphan designation: risvutatug rezetecan Treatment of pulmonary neuroendocrine carcinoma, 20/10/2025 Positive
Orphan designation: fenfluramine hydrochloride Treatment of Rett syndrome, 20/10/2025 Positive
Submitted by Anonymous (not verified) on 14 April 2026 - 16:00
Orphan designation: fenfluramine hydrochloride Treatment of Rett syndrome, 20/10/2025 Positive
Paediatric investigation plans: questions and answers
Submitted by Anonymous (not verified) on 14 April 2026 - 15:53
Paediatric investigation plans: questions and answers
Orphan designation: glial cell line-derived neurotrophic factor,sodium butyrate Treatment of Hirschsprung's disease, 20/10/2025 Positive
Submitted by Anonymous (not verified) on 14 April 2026 - 15:50
Orphan designation: glial cell line-derived neurotrophic factor,sodium butyrate Treatment of Hirschsprung's disease, 20/10/2025 Positive
Orphan designation: Unasnemab Treatment of amyotrophic lateral sclerosis, 20/10/2025 Positive
Submitted by Anonymous (not verified) on 14 April 2026 - 15:50
Orphan designation: Unasnemab Treatment of amyotrophic lateral sclerosis, 20/10/2025 Positive